Last reviewed · How we verify
JW0104+C2402
JW0104+C2402 is a Small molecule drug developed by JW Pharmaceutical. It is currently in Phase 3 development. Also known as: NA (Not Applicable).
JW0104+C2402's mechanism of action is not publicly available.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | JW0104+C2402 |
|---|---|
| Also known as | NA (Not Applicable) |
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on JW0104+C2402's mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia (PHASE3)
- To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JW0104+C2402 CI brief — competitive landscape report
- JW0104+C2402 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI
Frequently asked questions about JW0104+C2402
What is JW0104+C2402?
How does JW0104+C2402 work?
Who makes JW0104+C2402?
Is JW0104+C2402 also known as anything else?
What development phase is JW0104+C2402 in?
Related
- Manufacturer: JW Pharmaceutical — full pipeline
- Also known as: NA (Not Applicable)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing